Biomarker Assay Validation for Intra-Tumoral Quantification of Phosphorylated VEGFR-2
Découvrez nos ressources
Types de ressources
Thèmes
-
Download Case Study Biomarker Assay Validation for Intra-Tumoral Quantification of Phosphorylated VEGFR-2
-
Download Poster BRAF V600E Mutation Allele- Specific PCR Assay in Circulating Tumor Cells
BRAF V600E Mutation Allele- Specific PCR Assay in Circulating Tumor Cells
-
Download Poster AACR 2020 Poster: QuANTUM-R Biomarker Encore Poster
AACR 2020 Poster: QuANTUM-R Biomarker Encore Poster
-
Download Poster pKDR/KDR Ratio as Possible Predictor of Response in Phase I/II Study of Erlotinib and Bevacizumab for Recurrent or Metastatic Head and Neck Cancer
pKDR/KDR Ratio as Possible Predictor of Response in Phase I/II Study of Erlotinib and Bevacizumab for Recurrent or Metastatic Head and Neck Cancer
-
Download Poster Phase 1 Trial of a Combination of the VEGFR KinaseInhibitor Cediranib(AZD2171) and Bevacizumab in Advanced Malignancies
Phase 1 Trial of a Combination of the VEGFR KinaseInhibitor Cediranib(AZD2171) and Bevacizumab in Advanced Malignancies
%20and%20Bevacizumab%20in%20Advanced%20Malignancies.jpg?width=270&height=350&name=99.%20Phase%201%20Trial%20of%20a%20Combination%20of%20the%20VEGFR%20KinaseInhibitor%20Cediranib(AZD2171)%20and%20Bevacizumab%20in%20Advanced%20Malignancies.jpg)
-
Download Poster Prospective Real-time Analysis of P-cadherin Expression to Select Patients into a Phase I Oncology Trial
Prospective Real-time Analysis of P-cadherin Expression to Select Patients into a Phase I Oncology Trial
-
Download Poster Validation of a Gliadin α-I/α-II DQ2 Tetramer Flow Cytometric Assay a Biomarker to Asess Gluten Specific T Cells in Celiac Disease
Validation of a Gliadin α-I/α-II DQ2 Tetramer Flow Cytometric Assay a Biomarker to Asess Gluten Specific T Cells in Celiac Disease
-
Download Poster An Assay to Monitor the Engagement and Modulation of CD6 on T cells as a Clinical Biomarker of Treatment with Itolizumab
An Assay to Monitor the Engagement and Modulation of CD6 on T cells as a Clinical Biomarker of Treatment with Itolizumab
